Good morning, and welcome to the United Therapeutics Corporation First Quarter 2026 Corporate Update. My name is JL, and I will be your operator today. Please note that this call is being recorded. I'll now turn the webcast over to Harrison Silvers, Investor Relations at United Therapeutics.

Thank you, JL. Good morning. It is my pleasure to welcome you to the United Therapeutics Corporation First Quarter 2026 Corporate Update Webcast. Remarks today will include forward-looking statements representing our expectations or beliefs regarding future events. These statements involve risks and uncertainties that may cause actual results to differ materially. Our latest SEC filings, including Forms 10-K and 10-Q, contain additional information on these risks and uncertainties. We assume no obligation to update forward-looking statements. Today's remarks may discuss the progress and results of clinical trials or other developments with respect to our products. These remarks are intended solely to educate investors and are not intended to serve as the basis for medical decision-making or to suggest that any products are safe and effective for any unapproved or investigational uses. Full prescribing information for the products is available on our website. Accompanying me on today's call are Dr. Martine Rothblatt, our Chairperson and Chief Executive Officer; Michael Benkowitz, our President and Chief Operating Officer; James Edgemond, our Chief Financial Officer and Treasurer; Dr. Leigh Peterson, our Executive Vice President of Product Development and Xenotransplantation; and Pat Poisson, our Executive Vice President of Strategic Development. Note that James Edgemond and I will participate in a fireside chat and one-on-one meetings at the RBC Global Healthcare Conference in New York on May 19 as well as the Jefferies Global Healthcare Conference in New York on June 3. Our scientific, commercial and medical affairs teams will be present at the American Thoracic Society International Conference in Orlando, May 15 to the 21. Now I will turn the webcast over to Martine for an overview of our development pipeline and business activities. Martine?

Thank you, Harrison. Okay, folks, it's going to be a great and exciting call today. United Therapeutics is doing incredibly well—it is hard to imagine any other mid-cap biotech right now with prospects as good as ours. Here's what I mean. We just proved beyond a shadow of a doubt with a p-value of less than 0.0001 that we have two different therapeutics in two different diseases of substantial size, each of which has been shown to produce better clinical outcomes than any other drug ever approved for either indication. Wow, that's got to sink in. I personally have not seen anything like that from a single pharma company, all accomplished within six months. The two diseases we will be the best therapeutic for based on the completed Phase III trials are IPF with Tyvaso and PAH with ralinepag. Each of the two products will exceed our total revenues of today, a revenue run rate of $3 billion going to $4 billion by the end of 2027. Let's take ralinepag first. Every patient with PAH should be prescribed that once-daily pill because it actually gives them their best shot at clinical improvement. Specifically, we showed a threefold reduction in disease progression compared to background therapy. Ralinepag hit this and all other primary endpoints with better hazard ratios than selexipag and durably through four years. Frankly, this is the drug I dreamed of in starting United Therapeutics. This is why we've been calling ralinepag a super prostacyclin. There is simply no reason that virtually every PAH patient shouldn't be on it. Hence, I fully expect within two years of launch it will double our number of PAH patients to over 30,000 total. Next, let's look at Tyvaso for IPF. I said this will become the most prescribed drug for IPF because it improves forced vital capacity far more than the three existing drugs. It—and only it—boosted FVC by over 100 milliliters, and it did so quickly and durably. With tens of thousands of PAH patients and tens of thousands of IPF patients, it is nearly certain that these two drugs, once approved, will lap our 2027 $4 billion revenue run rate twice over. And coming right behind Tyvaso for IPF will be Tyvaso DPI for IPF and right behind that, Tyvaso SMI for IPF. Our goal is to leave no IPF patient behind regardless of how their particular body best absorbs Tyvaso. Now let's take a breath and reflect back on United Therapeutics. UT has been ahead of schedule as a habit. We were ahead of schedule on outcomes unblinding. We were ahead of schedule on TETON unblinding. And today, I am excited to announce another ahead of schedule, the next blockbuster product to emerge from stealth mode in our Skunk Works division—an inhaled formulation of our new chemical entity, ralinepag, called RALDPI. In stealth mode, a few months ago, we activated our exclusive option with MannKind for a second DPI. We now feel confident based on subsequent PK, computational biology via our proven CLIMB digital lung model and the results of the outcomes and TETON studies that this will be our biggest product ever. As you can see in the distributed market capture graph, we foresee our RALDPI product rising to tens of thousands of treated patients through PAH, ILD, IPF and PPF. Indeed, we will need all the capacity of the Danbury, Connecticut MannKind production plant and all the capacity of the new United Therapeutics North Carolina DPI facility to keep up with Tyvaso DPI and RALDPI demand. Now let's delve into the science to better appreciate what a generational product RALDPI will be for IPF. Ralinepag is the most potent member of the class of drugs that includes treprostinil. This is super clear from the extraordinary results of the outcome study. Second, it is now indisputable that this class of drugs via inhalation has significant antifibrotic effects as we proved in the two TETON trials. Ergo, we very reasonably and scientifically expect RALDPI to show after further clinical trials that it is the best-in-class treatment for IPF and PPF. The scientific reason lies in the chemical differences between the new ralinepag molecule and the old treprostinil molecule, both of which are digitally mirrored in our CLIMB predictive computational biology model. Ralinepag has eight fewer hydrogen atoms than treprostinil, but instead has a key nitrogen and a key chlorine atom that treprostinil lacks. These changes in molecular chemistry make all the difference in the world for pharmacodynamics and pharmacokinetics. Now treprostinil is a very, very good molecule, delivering very, very good results, but not our treprostinil, not Insmed's, not other liquid treprostinil—none of these can ever be the super prostacyclin that is ralinepag. It is just not in their chemistry, but it is in ralinepag's chemistry. It is this change in chemistry that makes ralinepag a generational product for IPF. In summary, UT's long-standing multiple shots-on-goal strategy has now yielded its greatest reward: a proven once-daily NCE in PAH formulated to use a proven DPI drug device for the best-in-disease treatment of the largest indications to which we aim. And as we march to this summit, we are rising through a series of great product stages that give us ever greater reach into the PAH and IPF community. Namely, we are rising through Tyvaso for ILD and IPF, Tyvaso DPI for ILD and IPF open-label extension, Tyvaso SMI or transmi for PAH, ILD and IPF and many more such combinations of products and diseases to treat, which are still in stealth mode in our Skunk Works division. Each incremental product indication platform that I just mentioned, each of these we are now aggressively developing for new and existing markets, and each of these brings UT ever closer to the ultimate goal depicted in the forecast chart released today. Thanks for listening and digesting all of this great science and great clinical development work. And now I'll turn to Michael to describe how the demand for our existing products from doctors and patients is strong as ever. Mike?

Thank you, Martine. That's a tough act to follow, but I'm going to do my best. Good morning, everyone. For the first quarter of 2026, we recorded $782 million in total revenue. Typical historical seasonality trends persisted in the first quarter, in addition to severe winter weather and pharmacy operations issues that slowed starts during the quarter. These have since been rectified, but it did impact our sales in the quarter, particularly in February. As discussed on our last earnings call, we expect to return to sequential growth in the near term. Turning to Tyvaso. Total revenue for the first quarter was $458 million. While sales of nebulized Tyvaso lagged a little bit over the quarter, Tyvaso DPI contributed 9% year-over-year growth, driven by an increase in patient demand. Looking at the competitive landscape, it's clear the market for inhaled prostacyclins is attractive and growing. We built and lead this market and expect our proven expertise to continue to win in the long term. We see this competitive dynamic as fuel for sharper execution across the organization, enhancing our strategic focus while operating with greater tactical intensity as we continue to shift momentum back in our favor. Speaking of momentum, we are seeing favorable trends in our underlying demand metrics. Coming out of the quarter, Tyvaso referrals or prescription rates are at approximately the same level they were before YUTREPIA launched. Patient shipments have grown for the last five months. Prescriber breadth and depth continue to grow, and we've seen a steady increase in patients graduating to higher doses of Tyvaso DPI with the launch of the 80-microgram single capsule and the 96-microgram and 112-microgram combination kits. Going forward, we're doubling down on what has always driven our success: relentless innovation, proven experience and patient obsession. Additionally, the sales force investments we're making in anticipation of the ralinepag and IPF approvals will be deployed in the middle of this year to focus on expanding our reach and capturing more of the large addressable but yet uncaptured market in PH-ILD and expanding share in PAH with our existing commercial portfolio. We've built a durable, high-performing commercial engine, and we're confident in our ability to expand our core business while driving the next wave of growth in treprostinil, ralinepag and IPF. To once again quickly recap, as Martine mentioned, both the TETON 1 and TETON 2 trials of nebulized Tyvaso in IPF were a resounding success and exceeded our highest expectations. We look forward to filing a supplemental new drug application by the end of this summer and believe the highly compelling body of evidence across both the TETON studies could warrant an expedited approval through priority review to bring this therapy to those patients in need as quickly as possible. If we receive a standard review timeline, we would expect to launch by Q2 of next year. And in parallel, we have already embarked on preparations for a product launch. Following IPF approval, we'll work with payers to secure coverage for the new indication as soon as possible. We recognize the substantial market opportunity that lies ahead, and we're fully prepared to seize it. Coming back to ADVANCE OUTCOMES, the unprecedented top-line results suggest ralinepag has the potential to revolutionize the treatment of pulmonary arterial hypertension as the first true once-a-day oral prostacyclin agonist. We believe this advancement could fundamentally shift the treatment paradigm, potentially positioning prostacyclins for earlier line usage in conjunction with ERAs and PDE-5s. With a differentiated clinical profile, combined with its convenient once-daily dosing, we foresee a multibillion-dollar opportunity in the market for oral ralinepag, where we expect to launch mid next year, assuming a smooth FDA approval on a standard review timeline. In summary, our goals over the near to medium term are to drive further growth in Tyvaso, the most prescribed inhaled prostacyclin, and after anticipated FDA approvals for ralinepag to become the most prescribed prostacyclin for PAH and for nebulized Tyvaso to become the most prescribed therapy for IPF. To close, I want to recognize the intensity, discipline and patient-first commitment our commercial and medical affairs teams bring every day. We remain confident that our business is positioned to deliver sustained double-digit long-term growth. With that, I'll pass the call back over to Harrison to start the Q&A session.

Thanks, Michael. Operator, if you want to assemble the roster and start with the first question.

Your first question comes from the line of Ash Verma of UBS.

Congrats on all the progress. Maybe just on the IPF regulatory filing and how you're positioning yourself in the market. I know you had previously mentioned that you would do a bridging study for the DPI. Where are we on that? Do you think that by the time you launch in IPF you would have the DPI format available? And just as a quick follow-up, I wanted to understand your thoughts on the JASCAYD or nintedanib launch metrics that are looking particularly strong. Do you think that is an indication of pent-up demand in this market, given there aren't many good options available? And how does Tyvaso get positioned compared to JASCAYD when you launch it?

All right. Thanks, Ash. Leigh, if you want to take the DPI to IPF component and then maybe Michael can follow up on JASCAYD.

Yes. So for the DPI strategy, we're actually working with FDA to come up with our bridging strategy for IPF with the Tyvaso DPI. I think we've been discussing that before. We will likely do healthy volunteer PK compatibility studies, comparability studies as well as patient studies to demonstrate safety and efficacy. As far as the sample size and duration of those studies, again, we're still working with FDA to come up with a clinical development plan.

Yes. Just on JASCAYD—I'm going to address the question that you had on JASCAYD. Yes, Ash, we've been following that very closely. I do think it's a good proxy or a good analog and does suggest that there is a lot of pent-up demand for new therapies in IPF, given what's currently on the market. So yes, I guess the short answer is we agree with you, and that's really how we're starting to think about potential launch curves. We're starting to have conversations with physicians now. It's still a little early because we were somewhat embargoed in what we could talk about with the New England Journal publication. But now that that's behind us, we're able to have those conversations. And I think we're hearing from physicians that they're very impressed by the data and very excited about bringing Tyvaso to market. I think we had an advisory board about a month or so ago where we had some of the top 15 IPF treaters in the country. We asked where they are going to use Tyvaso—first line, after JASCAYD, how they think about this—and they all said it's going to be patient dependent. In some cases, they would use Tyvaso first; in other cases, they may start JASCAYD. But at the end of the day, it doesn't matter because they fully expect that this disease is going to look a lot like what we see in PAH where it's combination therapy. So even if they're starting JASCAYD first, they're going to add Tyvaso on very quickly thereafter. So yes, we think the potential is, as Martine said in the beginning, just enormous in IPF.

Your next question comes from the line of Roanna Ruiz of Leerink Partners.

So I was curious: how does your overall commercial strategy and peak sales and timing expectations change now that you're focusing on a few different levers like the triple combo pill for ralinepag, DPI for ralinepag and also thinking about the SMI?

Thanks, Roanna, for the question. Good to hear your voice this morning. Michael, do you want to take that one?

Sure, Roanna. Yes, I think we'll provide more granularity as we start to build out our forecast and have more conversations with physicians about the different products and where they expect to use them. But at a high level, what Martine said in her opening remarks is right. If we're trending towards a $4 billion run rate by next year, we think certainly with just ralinepag and the IPF indication regardless of the delivery device, that puts us on a path to more than double revenues over the next few years. That's what we're building for and aiming for. How that breaks out between the different indications and different devices, I think we'll provide more granularity on that as we get later in the year and build out our models.

Your next question comes from the line of Jessica Fye of JPMorgan.

I wanted to focus on ralinepag DPI. Can you confirm this product coming out of stealth mode—is that the once-daily inhaled product you've been alluding to in prior quarters? When should we expect Phase I healthy volunteer PK/PD data comparing that product to oral ralinepag? And what led you to decide on DPI over SMI for ralinepag's new formulation?

Thanks, Jess. Good to hear from you. I'll kick that over to Pat to answer on ralinepag DPI plans.

So first, let me say we are excited to work with the MannKind development team again. What we were able to do together with Tyvaso DPI, which was approved in less than four years from our engagement while contending with the pandemic, was really nothing short of incredible, and we expect an even better encore with RALDPI. As mentioned in the MannKind press release this morning, we began work on RALDPI about six months ago. We've made great progress with the completion of formulation development and the transition into manufacturing tox study supplies. We've had a very positive pre-IND engagement with FDA, and we'll shortly be moving into some minimal nonclinical testing, which will be quickly followed by an IND in a Phase I study, which we believe will be completed before the end of the year. We believe the half-life of ralinepag, along with some other characteristics we are investigating, are very promising for this to be a once-a-day product. Important to note that this will be without the addition of any release-controlling materials, which need to be carefully studied for safety when used chronically. So I'll finish with, as they say in iCar racing, we are staying with hard tires and not making any pit stops.

Your next question comes from the line of Joseph Thome of TD Cowen.

Maybe just to extend a little bit on the development program for RALDPI. How quickly can this move? Is the availability of the data for oral ralinepag helpful at all, maybe specifically for PAH? Could you go right into registration? Just trying to think about timelines relative to some competitors in the space.

Joe, thanks for the question this morning. I'll kick that back over to Pat again.

Another great question. Of course, the ADVANCE OUTCOMES data was exceptional and that's very encouraging that RALDPI will be effective to treat PAH, PH-ILD, IPF and PPF. As far as timing, long term, we're going to be able to move into PAH fairly quickly relative to typical pharma timelines as we'll be pursuing that approval alongside the solid dose. Certainly, the solid dose has been a big contributor to our engagement with FDA and really the minimal amount of pre-IND work that we have to do for RALDPI. I anticipate we'll complete the initial Phase I study by the end of the year, and we'll be rapidly able to kick off studies for PAH efficacy as well as PH-ILD, IPF and PPF. Each of those will progress at different paces, but initially, PAH will be the first approval.

Your next question comes from the line of Lisa Walter of RBC Capital Markets.

On the once-daily ralinepag DPI, can you share more color on the formulation? Should we think of this as a ralinepag prodrug or another formulation with a lung-targeting ligand? Or are relatively few additional flourishes needed to make ralinepag inhalable? Any color here would be helpful.

Thanks, Lisa. Good to hear from you. Pat, you're the star of the show today.

All right. We'll be leveraging MannKind's crystal carrier IP for ralinepag, very similar to what we have for treprostinil. It is not going to be a prodrug. Perhaps we may investigate other polymorphs of ralinepag in the future, but initially, it's going to be the ralinepag molecule that we investigated for solid dose. So again, very similar formulation to the current treprostinil, using MannKind's crystal carrier IP.

Your next question comes from the line of Olivia Brayer of Cantor.

Now that you are committing to developing a number of different formulations in IPF going forward, can you talk about which you think have the highest chances for success? How are you thinking about nebulized versus DPI versus SMI and then also Tyvaso versus ralinepag for IPF patients specifically? And from a regulatory strategy perspective, anything you can say yet about getting some of these next formulations to patients? It sounds like a bridging study for DPI, but what about the SMI formulation? And when could you realistically start those ralinepag studies in IPF and PPF?

Perhaps from a broader strategic standpoint, Michael can take that question and then Leigh can follow up on the regulatory side.

I think from a strategic standpoint, our approach to IPF is very similar to what you've seen us do over the last 30 years in PAH, which is a multiple shots-on-goal approach. We started with Remodulin IV, progressed to Remodulin subcutaneous, then Tyvaso and Orenitram, then Tyvaso DPI and now ralinepag. The point of all that is that we've uncovered in PAH—and we think it's true in IPF—that patients are like snowflakes: they're not a homogenous group who all respond to the same drug delivery approach. There's a role for all of these products. I think that's what we'll see in IPF. We take multiple shots on goal because patients respond differently to different drugs and delivery devices. Our approach is agnostic as to which one they choose, as long as they're choosing one of our products. Strategically, that's how we think about different devices, different NCEs and IPF.

I just wanted to add a little color to what Michael said. Keep in mind the different categories: inhaled route versus oral route. Oral, especially if once a day, tends to be more convenient, but we also know that systemic vasodilators are generally contraindicated in patients with PH-ILD or IPF given the potential for worsening ventilation-perfusion mismatch. That tends to separate the population and suggests inhaled approaches will be more appropriate for certain patients. Regarding powder versus SMI, some patients may prefer one for convenience or cough sensitivity; others may be more sensitive to powder versus nebulizer. Even though treprostinil and ralinepag are in the same class, they bind receptors differently—ralinepag is a very potent IP receptor agonist, whereas treprostinil binds multiple receptors including IP and EP2. There may be differences in efficacy based on patient genetics. All of these factors allow us to tailor treatment to individual patients. On the mechanistic side, there's preclinical data that IP receptor activation promotes alveolar regeneration during lung repair, and there are pathways—such as p53-related pathways—where these molecules differ. So we're seeing more evidence for potentially distinct mechanisms of action across these indications. As far as regulatory strategy, Pat may want to add, but from our perspective, these differences justify developing multiple options for patients.

I mean the regulatory strategy would proceed as expected. We'll have nebulized Tyvaso approved in IPF and we'll conduct whatever agreed-upon bridging study is necessary for DPI and then proceed directly with the filing from there. I don't anticipate anything unusual.

Thank you, Pat, Leigh and Michael—three really wonderful answers. Operator, I think one more question we have time for.

Your last question comes from the line of Roger Song of Jefferies.

Congrats on the quarter. In the update you also have the PH-COPD Phase II about to start later this year. How should we think about the market opportunity and what is the product formulation potential sequence for that indication, given we haven't talked about a lot of the combination device and drug?

Thanks, Roger. Leigh, perhaps you want to share a little bit of color on the PH-COPD study?

Yes. For the formulation, we're planning to use treprostinil SMI for PH-COPD. We're planning to run the study in a couple of phases. We have a Phase I already ongoing with the treprostinil SMI in healthy volunteers. Then we'll plan a Phase II study with PH-COPD patients, which will be followed by a Phase III PH-COPD study. We have several learnings from over the years that are being considered here with regard to patient populations, and we're really looking forward to starting these studies with enriched patient population eligibility criteria.

Thank you, Leigh. Operator, you can go ahead and close the call.

Thank you for participating in today's United Therapeutics Corporation earnings webcast. A rebroadcast of this webcast will be available for replay for one week by visiting the Events and Presentations section of the United Therapeutics Investor Relations website at ir.unither.com. This concludes today's conference call. You may now disconnect.